Travere Therapeutics Stock Earnings Reports

Travere reported a strong start to 2026 driven by commercial momentum and pipeline progress. Key commercial highlights: FILSPARI received the first full FDA approval for FSGS (for adults and children ≥8 without active nephrotic syndrome), expanding the addressable population alongside its established IgA nephropathy indication; Q1 demand was record-high with 993 new patient start forms and approximately $105.2M in U.S. FILSPARI sales (up ~88% year-over-year). Management expects the combined IgA nephropathy and FSGS opportunity to cover >100,000 U.S. patients and estimates a ~$3 billion potential peak sales opportunity for FILSPARI. Payer access and early reimbursement for FSGS have been encouraging, with field feedback pointing to faster uptake in FSGS versus the original IgA nephropathy launch. Pipeline and development: enrollment restarted in the pivotal Phase III HARMONY study of pegtibatinase for classical homocystinuria (first new patient dosed), with top-line data expected in 2027; earlier-phase data support substantial homocysteine reductions and potential disease-modifying benefit. Financials and operations: total Q1 revenue was $127.2M (including $124.5M net product sales), R&D and SG&A increased due to HARMONY restart and FSGS launch investments, non‑GAAP net income was $4.1M for the quarter, and the company reported approximately $352M in cash, cash equivalents, marketable securities, and receivables (cash balance ~ $264.7M as of March 31). Management reiterated priorities: grow FILSPARI in IgA nephropathy, execute the FSGS launch, and advance HARMONY while maintaining disciplined investment.